Skip to main content
OCGN
NASDAQ Life Sciences

Ocugen 将于 3 月 24 日展示地理性萎缩的 OCU410 基因治疗 2 期数据

feedReported by GlobeNewswire
Sentiment info
Neutral
Importance info
7
Price
$2.06
Mkt Cap
$668.91M
52W Low
$0.531
52W High
$2.725
Market data snapshot near publication time

summarizeSummary

Ocugen 宣布将于 3 月 24 日举办网络播出会，讨论其地理性萎缩的基因治疗药物 OCU410 的全部 2 期临床试验数据。该事件为公司建立了一个重要的近期催化剂，因为 OCU410 代表了其基因治疗产品线的关键资产。考虑到 Ocugen最近在其 10-K 中的“持续经营”警告，该中期临床数据的结果和解释对于其未来前景至关重要，并可能对投资者情绪和公司估值产生重大影响。专业交易员将密切关注网络播出会，以获取有关 OCU410疗效和安全性特征的详细见解。

在该公告发布时，OCGN的交易价格为$2.06，交易所为NASDAQ，所属行业为Life Sciences，市值约为$6.7亿。 52周交易区间为$0.53至$2.73。 这则新闻被评估为中性市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed OCGN - Latest Insights

OCGN
Apr 28, 2026, 7:01 AM EDT
Filing Type: DEFA14A
Importance Score:
7
Ocugen's Annual Meeting Proxy Omits Reverse Stock Split Proposal
Sentiment: Negative
View Wiseek Article
OCGN
Apr 20, 2026, 5:18 PM EDT
Filing Type: PRER14A
Importance Score:
8
Ocugen Amends Reverse Stock Split Proposal, Lowers Minimum Ratio to 1:2 Amidst Going Concern
Sentiment: Negative
View Wiseek Article
OCGN
Apr 17, 2026, 4:56 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Ocugen Seeks Shareholder Approval for Reverse Stock Split Amidst Going Concern Warning
Sentiment: Negative
View Wiseek Article
OCGN
Mar 27, 2026, 6:03 AM EDT
Source: Wiseek News
Importance Score:
8
Ocugen Completes Phase 3 Enrollment for Two Gene Therapies, Targets Three BLA Submissions by 2028
Sentiment: Positive
View Wiseek Article
OCGN
Mar 26, 2026, 7:13 PM EDT
Filing Type: 8-K
Importance Score:
8
Ocugen Details Positive OCU410 Phase 2 Data & Comprehensive Gene Therapy Pipeline in Investor Presentation
Sentiment: Positive
View Wiseek Article
OCGN
Mar 24, 2026, 7:45 AM EDT
Source: GlobeNewswire
Importance Score:
9
OCU410 Gene Therapy Reduces Geographic Atrophy Lesion Growth by 31% in Positive Phase 2 Data; Ocugen to Advance to Phase 3
Sentiment: Positive
View Wiseek Article
OCGN
Mar 23, 2026, 7:02 AM EDT
Source: GlobeNewswire
Importance Score:
7
Ocugen to Present Phase 2 OCU410 Gene Therapy Data for Geographic Atrophy on March 24
Sentiment: Neutral
View Wiseek Article
OCGN
Mar 20, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Ocugen Secures $15M from Warrant Exercise, Extends Cash Runway Amidst Going Concern
Sentiment: Positive
View Wiseek Article
OCGN
Mar 04, 2026, 3:03 PM EST
Source: Wiseek News
Importance Score:
9
Ocugen Reports Positive OCU410 Phase 2 Data, Secures Cash Runway Beyond 2026
Sentiment: Positive
View Wiseek Article
OCGN
Mar 04, 2026, 11:38 AM EST
Filing Type: 10-K
Importance Score:
9
Ocugen's 10-K Reveals Going Concern, Limited Cash Runway, and Ongoing Legal Battle Over Share Count
Sentiment: Negative
View Wiseek Article